Skip to content
Visionary Ventures
Venture capital fund investing life sciences focusing in ophthalmology medical devices and pharmaceuticals.
Visionary VenturesVisionary Ventures
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN
Fund Menu
Search
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN

Monthly Archives: May 2020

Tarsus Presents Positive Phase IIb Results of TP-03

News, TarsusBy Garrett HamontreeMay 26, 2020

Tarsus Presents Positive Results of the Jupiter Study, a Phase 2b Randomized Controlled Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Blepharitis Due to Demodex Infestation, at AOA 2020 Virtual Meeting

Elad Kedar and Jeffry Weinhuff, the CEO and Chairman of Orasis Interviewed on OIS Podcast

News, OrasisBy Garrett HamontreeMay 20, 2020

Elad Kedar, CEO of Orasis Pharmaceuticals shares his strategy for successfully completing a Phase 2b clinical study in preparation of their phase 3 of CSF-1 drops for temporary correction of presbyopia. Jeffry Weinhuff from Visionary Ventures joins the conversation as Chairman of the Board to explain how he evaluated the Orasis technology and what VCs look for.

Ophthalmology Investing in Orange County in Orange County Business Journal Article

News, VisionaryBy Garrett HamontreeMay 19, 2020

Orange County Business Journal (OCBJ) interviews Visionary Ventures managing partner Jeffry Weinhuff and a Flying L managing partner Bill Link about investing in ophthalmology.

  • Home
  • Ophthalmology
  • Team
    • Investment Committee
    • Visionary KOLs
    • Fund Management
  • Portfolio
  • News
  • Contact
  • Investor Portal
Footer Menu

© 2019 Visionary Ventures. All Rights Reserved.

Go to Top